Average stock performance after each discretionary buy, measured at 1, 3 and 6 months. 16 buys in history.
Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| DOV PHARMACEUTICAL INC | 1,509,292 | reported | 19 Nov 2008 | tx 14+1,783,029 |
| Cyteir Therapeutics, Inc. | 227,439 | reported | 06 Feb 2024 | tx 17+178,472−214,150 |
| AMARIN CORP PLC\UK | 196,547 | reported | 15 Dec 2021 | tx 104+4,906,811−6,106,083 |
| INSULET CORP | 30,558 | reported | 17 May 2017 | tx 34+137,905−85,000 |
| SANGAMO THERAPEUTICS, INC | 25,000 | reported | 25 Feb 2022 | tx 16+199,600 |
| LIPOSCIENCE INC | 0 | reported | 20 Nov 2014 | tx 3+25,372−25,372 |
| ACCELERON PHARMA INC | 0 | reported | 19 Nov 2021 | tx 37+138,406−147,156 |
| AN2 Therapeutics, Inc. | 0 | reported | 19 Mar 2026 | tx 19+417,759−332,302 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 19 Mar 2026 | GRANT_AWARD | AN2 Therapeutics, Inc. | 99,999 | — | deriv |
| 19 Mar 2026 | OTHER | AN2 Therapeutics, Inc. | 23,742 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | AN2 Therapeutics, Inc. | 23,742 | — | deriv |
| 19 Mar 2026 | OTHER | AN2 Therapeutics, Inc. | 10,362 | — | deriv |
| 19 Mar 2026 | GRANT_AWARD | AN2 Therapeutics, Inc. | 10,362 | — | deriv |
| 19 Mar 2026 | OTHER | AN2 Therapeutics, Inc. | 99,999 | — | deriv |
| 20 Feb 2026 | GRANT_AWARD | AN2 Therapeutics, Inc. | 20,400 | 0.00 USD | deriv |
| 22 May 2025 | GRANT_AWARD | AN2 Therapeutics, Inc. | 19,111 | 0.00 USD | deriv |
| 10 Apr 2025 | GRANT_AWARD | AN2 Therapeutics, Inc. | 10,523 | 0.00 USD | |
| 19 Dec 2024 | GRANT_AWARD | AN2 Therapeutics, Inc. | 9,816 | 0.00 USD | |
| 27 Nov 2024 | PURCHASE | AN2 Therapeutics, Inc. | 2,000 | 1.40 USD | |
| 19 Nov 2024 | PURCHASE | AN2 Therapeutics, Inc. | 5,000 | 1.01 USD | |
| 18 Nov 2024 | PURCHASE | AN2 Therapeutics, Inc. | 20,000 | 1.00 USD | first after silence |
| 19 Jun 2024 | GRANT_AWARD | AN2 Therapeutics, Inc. | 64,503 | 0.00 USD | deriv |
| 06 Feb 2024 | EXERCISE | Cyteir Therapeutics, Inc. | 14,150 | 1.69 USD | |
| 06 Feb 2024 | EXERCISE | Cyteir Therapeutics, Inc. | 14,150 | 0.00 USD | deriv |
| 18 Jan 2024 | SALE | AN2 Therapeutics, Inc. | 100,000 | 19.11 USD | |
| 07 Jun 2023 | GRANT_AWARD | AN2 Therapeutics, Inc. | 23,742 | 0.00 USD | deriv |
| 03 Feb 2023 | GRANT_AWARD | Cyteir Therapeutics, Inc. | 14,150 | 0.00 USD | deriv |
| 07 Dec 2022 | PURCHASE | Cyteir Therapeutics, Inc. | 21,202 | 1.30 USD | |
| 12 May 2022 | GRANT_AWARD | AN2 Therapeutics, Inc. | 10,362 | 0.00 USD | deriv |
| 12 May 2022 | PURCHASE | Cyteir Therapeutics, Inc. | 743 | 1.61 USD | |
| 11 May 2022 | PURCHASE | Cyteir Therapeutics, Inc. | 1,000 | 1.70 USD | |
| 10 May 2022 | PURCHASE | Cyteir Therapeutics, Inc. | 49,406 | 1.89 USD | |
| 29 Mar 2022 | CONVERSION | AN2 Therapeutics, Inc. | 98,199 | — |
5 purchases reported after at least 12 months of silence — most recent on 18 Nov 2024.